Naresh Konduru

Dr. Naresh Konduru

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Biomedical Chromatography
Verified
Journal Article
Closed access
LKLeela Prasad Kowtharapu
Leela Prasad Kowtharapu
NKNaresh Kumar Katari
Naresh Kumar Katari
SCSurekha Ch.
Surekha Ch.
CSChristian A. Sandoval
Christian A. Sandoval
SMSiva Krishna Muchakayala
Siva Krishna Muchakayala
NKNaresh Konduru
Naresh Konduru


6 September 2021 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
VSVelusamy B. Subramanian
Velusamy B. Subramanian
NKNaresh Kumar Katari
Naresh Kumar Katari
VPVijetha Ponnam
Vijetha Ponnam
NKNaresh Konduru
Naresh Konduru
TDThirupathi Dongala
Thirupathi Dongala
GVGovind Vyas
Govind Vyas


24 January 2023 in Biomedical Chromatography
Verified
Journal Article
Closed access
rathnakar nathirathnakar nathi
rathnakar nathi
LKLeela Prasad Kowtharapu
Leela Prasad Kowtharapu
SMSiva Krishna Muchakayala
Siva Krishna Muchakayala
NKNaresh Konduru
Naresh Konduru

15 December 2022 in ACS Omega
Verified
Journal Article
Open access
DVDivya Kumar Vemuri
Divya Kumar Vemuri
PAParameswari Akshinthala
Parameswari Akshinthala
NKNaresh Konduru
Naresh Konduru
LKLeela Prasad Kowtharapu
Leela Prasad Kowtharapu
NKNaresh Kumar Katari
Naresh Kumar Katari
RGRambabu Gundla
Rambabu Gundla
Pibrentasvir (PIB) was approved for treating hepatitis C patients. A specific, accurate, linear, robust, and stability-indicating method was developed and validated for determining degradation impurities present in the PIB drug substance by studying the quality by design (QbD) principles. All identified degradation impurities were separated with the stationary phase HALO C18, 150 mm × 4.6 mm, 2.7 μm. Mobile phase A contains pH 2.5 phosphate buffer and acetonitrile in the ratio of (70:30, v/v), and mobile phase B contains water and acetonitrile in the ratio of (30:70, v/v), respectively. The chromatographic conditions were optimized, such as flow rate of 0.8 mL/min, UV detection at 252 nm, injection volume of 20 μL, and column temperature of 40 °C. The proposed method was validated per the current ICH Q2 (R1) guidelines. The recovery study and linearity ranges were established from limit of quantification (LOQ) to 300% optimal concentrations. The method validation results were between 98.6% and 106.2% for recovery, and linearity r 2 was more than 0.999 for all identified impurities. The method precision results achieved below 5% relative standard deviation (RSD). The forced degradation results demonstrated that the drug was sensitive to chemical stress conditions. During the stress study, degrading impurities were identified by the LC-MS technique and the mechanism pathway. A QbD-based experimental design (DoE) approach was used to establish the robustness of the method.